{"id":5099,"date":"2023-09-07T15:26:56","date_gmt":"2023-09-07T15:26:56","guid":{"rendered":"https:\/\/event.roseliassociates.com\/nci-dcb-somatic-mutations-ws-2024\/?page_id=5099"},"modified":"2024-05-03T13:57:45","modified_gmt":"2024-05-03T13:57:45","slug":"home","status":"publish","type":"page","link":"https:\/\/event.roseliassociates.com\/nci-dcb-stromal-mutations-ws-2024\/","title":{"rendered":"Home"},"content":{"rendered":"

<\/div><\/div><\/span>

Home<\/h1><\/span>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>


\nPurpose<\/b><\/p>\n

The key impetus for this Workshop is that research aimed at understanding stromal mutations at different stages of tumor evolution \u2013 from initiation to metastasis and treatment resistance \u2013 lags severely behind that of traditional cancer cell mutations. Notably, strategies on characterizing the stromal elements \u2013 within the mutation-signaling continuum \u2013 that are contributing to these various stages of tumorigenesis remain understudied, despite published (yet historical and anecdotal) evidence in support of this notion. Studies on \u201cstromal effects\u201d are often limited to measuring and\/or testing for short term\/acute biological and biochemical reprogramming and remodeling events linked to stromal cell state(s), stromal landscape\/fibrosis, and immune\/inflammatory responses. Missing from the analyses is the longer-term implications and ramifications of stromal cell mutational status \u2013 be it somatic or germline and\/or nuclear or mitochondrial. With the recent technological advances in single-cell technologies, multiparameter imaging, and ability to integrate multi-omics with spatial TME context, the cancer research field is now well positioned to interrogate and detect stroma cell mutation(s) as an added \u2013 but missing \u2013 layer of cancer predispositions, and dynamic complexities.<\/strong><\/p>\n

Consequently, the purpose of this Workshop is to bring together a community of tumor-stromal biologists and technology experts to:<\/strong><\/p>\n

1. Discuss the state of the science;<\/strong><\/p>\n

2. Evaluate the technological advancements facilitating scientific progress, along with challenges and limitations; and<\/strong><\/p>\n

3. Reach a consensus on key priorities in the field of stromal cell states with an emphasis on pro-tumoral (or tumor suppressive) stroma function driving mutations across the nuclear-mitochondrial genomes.<\/strong><\/p>\n<\/div>


Agenda<\/b><\/p>\n

All times are in EDT.<\/p>\n<\/div>

\u00a0<\/p>\n

\u00a0<\/p>\n<\/div>\n

\n

May 2nd<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
               Day 1<\/b><\/th>\n <\/th>\n <\/th>\n<\/tr>\n<\/thead>\n
11:30 AM \u2013 11:45 AM<\/td>\nWelcome<\/td>\n\n

Dan Gallahan<\/p>\n

Mihoko Kai<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n

11:45 AM \u2013 12:00 PM<\/td>\nLogistics<\/span><\/span> <\/span><\/td>\n\n

Mihoko Kai<\/p>\n

Christina George<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n

12:00 PM \u2013 12:15 PM<\/td>\nOverview<\/span> 1<\/span>-Why stroma<\/span>l<\/span> m<\/span>utations<\/span> (and other genomic alterations)<\/span>?<\/span><\/span><\/td>\n\n

Edna Cukierman<\/p>\n

David Goodrich<\/p>\n<\/td>\n<\/tr>\n

Stromal Mutations & DNA Repair<\/em><\/strong><\/td>\n <\/td>\n\n

Kai Kessenbrock<\/p>\n

Mihoko Kai<\/p>\n<\/td>\n<\/tr>\n

12:15 PM \u2013 1:00 PM<\/td>\nNon-cell autonomous TME alterations from stroma<\/span>l<\/span> cell mutations<\/span><\/span><\/td>\nJan van Deursen<\/td>\n<\/tr>\n
1:00 PM \u2013 1:45 PM<\/td>\nThe role of aged stroma\/microenvironment in cancer initiation and progression<\/span><\/span><\/td>\nPeter Adams<\/td>\n<\/tr>\n
1:45 PM \u2013 2:00 PM<\/td>\nBreak<\/td>\n <\/td>\n<\/tr>\n
Systemic conditions<\/em><\/strong><\/td>\n <\/td>\n\n

Edna Cukierman<\/p>\n

Christina George<\/p>\n<\/td>\n<\/tr>\n

2:00 PM \u2013 2:45 PM<\/td>\nStromal drivers of immune escape <\/span>during breast tumor progression<\/span><\/span><\/td>\nKornelia Polyak<\/td>\n<\/tr>\n
2:45 PM \u2013 3:30 PM<\/td>\nAge-related stromal changes drive breast cancer<\/td>\nSheila Stewart<\/td>\n<\/tr>\n
3:30 PM \u2013 4:15 PM<\/td>\nCancer-associated but not cancer-specific: Activated fibroblasts<\/td>\nBoris Hinz<\/td>\n<\/tr>\n
4:15 PM \u2013 5:15 PM<\/td>\nWorking group A discussion<\/td>\nDavid Goodrich<\/td>\n<\/tr>\n
5:15 PM \u2013 5:30 PM<\/td>\nRemarks (Group A) and adjourn for the day<\/td>\nDavid Goodrich<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
<\/div><\/div>

\u00a0<\/p>\n

\u00a0<\/p>\n<\/div>\n

\n

May 3rd<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
               Day 2<\/b><\/th>\n <\/th>\n <\/th>\n<\/tr>\n<\/thead>\n
10:00 AM \u2013 10:15 AM<\/td>\nWelcome<\/td>\n\n

Mihoko Kai<\/p>\n<\/td>\n<\/tr>\n

10:15 AM \u2013 10:45 AM<\/td>\nOverview 2 \u2013 Advance in technologies<\/td>\n\n

Kai Kessenbrock<\/p>\n

Nick Navin<\/p>\n<\/td>\n<\/tr>\n

Tech, Cancer Mutation, Evolution, Plasticity<\/em><\/strong><\/td>\n <\/td>\n\n

David Goodrich<\/p>\n

Nick Navin<\/p>\n<\/td>\n<\/tr>\n

10:45 AM \u2013 11:30 AM<\/td>\nGenetic changes in non-epithelial cells of human body<\/span><\/span><\/td>\nFuchou Tang<\/td>\n<\/tr>\n
11:30 AM \u2013 12:15 PM<\/td>\nSingle-molecule mutation analysis as a genome integrity measure<\/span><\/span><\/td>\nAlex Maslov<\/td>\n<\/tr>\n
12:15 PM \u2013 1:00 PM<\/td>\nTracking Clonality in tumors and their microenvironments<\/td>\nKen Lau<\/td>\n<\/tr>\n
1:00 PM \u2013 1:30 PM<\/td>\nBreak<\/td>\n <\/td>\n<\/tr>\n
1:30 PM \u2013 2:30 PM<\/td>\nWorking group B discussion<\/td>\nNick Navin<\/td>\n<\/tr>\n
2:30 PM \u2013 2:45 PM<\/td>\nRemarks (Group B)<\/td>\nNick Navin<\/td>\n<\/tr>\n
2:45 PM \u2013 3:00 PM<\/td>\nBreak<\/td>\n <\/td>\n<\/tr>\n
3:00 PM \u2013 3:30 PM<\/td>\nConcluding discussion<\/td>\n\n

Edna Cukierman<\/p>\n

Kai Kessenbrock<\/p>\n

David Goodrich<\/p>\n

Nick Navin<\/p>\n<\/td>\n<\/tr>\n

3:30 PM \u2013 4:00 PM<\/td>\nClosing remarks and meeting adjourned<\/td>\n\n

Edna Cukierman<\/p>\n

Kai Kessenbrock<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div><\/div><\/div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"footnotes":""},"class_list":["post-5099","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/event.roseliassociates.com\/nci-dcb-stromal-mutations-ws-2024\/wp-json\/wp\/v2\/pages\/5099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/event.roseliassociates.com\/nci-dcb-stromal-mutations-ws-2024\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/event.roseliassociates.com\/nci-dcb-stromal-mutations-ws-2024\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/nci-dcb-stromal-mutations-ws-2024\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/nci-dcb-stromal-mutations-ws-2024\/wp-json\/wp\/v2\/comments?post=5099"}],"version-history":[{"count":46,"href":"https:\/\/event.roseliassociates.com\/nci-dcb-stromal-mutations-ws-2024\/wp-json\/wp\/v2\/pages\/5099\/revisions"}],"predecessor-version":[{"id":5612,"href":"https:\/\/event.roseliassociates.com\/nci-dcb-stromal-mutations-ws-2024\/wp-json\/wp\/v2\/pages\/5099\/revisions\/5612"}],"wp:attachment":[{"href":"https:\/\/event.roseliassociates.com\/nci-dcb-stromal-mutations-ws-2024\/wp-json\/wp\/v2\/media?parent=5099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}